Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KALUMI: KAF156 and LUM-SDF in Pediatric Uncomplicated Plasmodium Falciparum Malaria
NCT04546633Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of ganaplacide in malaria (4 arms), sponsored by Novartis. Primary endpoint: Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response at Day 43. Started Feb 2021; status: completed.
02
Drugs
ganaplacide
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04546633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546633.